Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00616135
Other study ID # RESTORE-2
Secondary ID
Status Completed
Phase Phase 4
First received February 5, 2008
Last updated May 13, 2011
Start date June 2008
Est. completion date November 2010

Study information

Verified date May 2011
Source Cytori Therapeutics
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

A post-marketing study evaluating the transplantation of autologous fat augmented with Adipose Derived Regenerative Cells (ADRCs), in patients with functional and cosmetic breast deformities post segmental mastectomy or quadrantectomy (lumpectomy).


Recruitment information / eligibility

Status Completed
Enrollment 71
Est. completion date November 2010
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Females with a history of T2N0M0 breast carcinoma (tumor =3 cm in largest dimension)

- Surgical or endoscopic segmental mastectomy or quadrantectomy (lumpectomy)

- Clean surgical margins

- No prosthesis in breast(s) to undergo treatment

- Ability to undergo lipoaspiration

- Last treatment for breast cancer = 12 months prior to enrollment with absence of recurrence (patients on anti-estrogen adjuvant therapy are NOT excluded)

- No evidence of recurrence of cancer based on mammogram or breast exam prior to enrollment

- Objective signs of mild breast damage post Breast Conservation Therapy

- Type I Cosmetic Sequelae Classification

- A minimum of 1 cm of soft tissue (e.g. breast or fat) is available between the skin and chest wall at the recipient site

- A minimum of two-thirds of the breast is remaining post Breast Conservation Therapy

- No continuous adhesion of skin to bone >3 cm in diameter

- The volume and shape of the defect(s) must be conducive to correction during a single treatment session (maximum defect volume =150 mL in breast(s) to undergo treatment)

Exclusion Criteria:

- History of autoimmune disorder (e.g., Systemic Lupus Erythematosus [SLE])

- History of connective, metabolic or atrophic skin disease

- History of keloid scarring

- Chronic use (>7 consecutive days) of anticoagulants (such as aspirin) or NSAIDs within 15 days prior to enrollment

- Life expectancy = 2 years

- Recurrence or active malignancy requiring radiation or surgical treatment =12 months prior to enrollment

- Presence of any other known malignancy

- Body Mass Index (BMI) >30

- Plan to undergo weight reduction surgery or foresee any significant weight changes during the study (defined as changes in BMI >5 compared to baseline

- Presence of contraindications to MRI

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
ADRC-Enhanced Autologous Fat Transplant
Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.

Locations

Country Name City State
Belgium Jules Bordet Institute of Cancer Brussels
Italy Università degli Studi di Firenze Florence
Spain Hospital General Universitario Gregorio Marañon Madrid
Spain Instituto Valenciano Oncologia Valencia
United Kingdom Glasgow Royal Infirmary Glasgow Scotland

Sponsors (1)

Lead Sponsor Collaborator
Cytori Therapeutics

Countries where clinical trial is conducted

Belgium,  Italy,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient and physician satisfaction with functional and cosmetic results. Improvement in overall breast deformity measured at 12 months compared to baseline. 12 months No
Secondary Change in breast volume and shape at 6 and 12 Months compared to baseline. Improvement in skin pigmentation abnormalities at 6 and 12 months compared to Baseline. Improvement in overall breast deformity at 6 Months compared to Baseline. 6 months and 12 months No
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05558917 - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery N/A
Active, not recruiting NCT03664778 - Abbreviated Breast MRI After Cancer Treatment
Recruiting NCT03144622 - 18F-FSPG PET/CT Imaging in Patients With Cancers
Completed NCT05452499 - Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae N/A
Active, not recruiting NCT04568902 - Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Phase 1
Completed NCT02860585 - Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation N/A
Completed NCT04059809 - Photobiomodulation for Breast Cancer Radiodermatitis Phase 2/Phase 3
Recruiting NCT04557449 - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors Phase 1/Phase 2
Completed NCT03698942 - Delphinus SoftVueâ„¢ ROC Reader Study
Completed NCT00092950 - Exercise in Women at Risk for Breast Cancer Phase 2
Terminated NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Not yet recruiting NCT02151071 - The Breast Surgery EnLight and LightPath Imaging System Study Phase 1/Phase 2
Recruiting NCT02934360 - TR(ACE) Assay Clinical Specimen Study N/A
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Not yet recruiting NCT02876848 - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study) N/A
Completed NCT02931552 - Nuevo Amanecer II: Translating a Stress Management Program for Latinas N/A
Recruiting NCT02547545 - Breast Cancer Chemotherapy Risk Prediction Mathematical Model N/A
Completed NCT02303366 - Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 Phase 1
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Completed NCT02518477 - Preventive Intervention Against Lymphedema After Breast Cancer Surgery N/A